Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound

Maria Loiarro, Federica Capolunghi, Nicola Fantò, Grazia Gallo, Silvia Campo, Brunilde Arseni, Rita Carsetti, Paolo Carminati, Rita De Santis, Vito Ruggiero, Claudio Sette

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

MyD88 is an adaptor protein, which plays an essential role in the intracellular signaling elicited by IL-1R and several TLRs. Central to its function is the ability of its Toll/IL-1R translation initiation region (TIR) domain to heterodimerize with the receptor and to homodimerize with another MyD88 molecule to favor the recruitment of downstream signaling molecules such as the serine/threonine kinases IL-1R-associated kinase 1 (IRAK1) and IRAK4. Herein, we have synthesized and tested the activity of a synthetic peptido-mimetic compound (ST2825) modeled after the structure of a heptapeptide in the BB-loop of the MyD88-TIR domain, which interferes with MyD88 signaling. ST2825 inhibited MyD88 dimerization in coimmunoprecipitation experiments. This effect was specific for homodimerization of the TIR domains and did not affect homodimerization of the death domains. Moreover, ST2825 interfered with recruitment of IRAK1 and IRAK4 by MyD88, causing inhibition of IL-1β-mediated activation of NF-κB transcriptional activity. After oral administration, ST2825 dose-dependently inhibited IL-1β-induced production of IL-6 in treated mice. Finally, we observed that ST2825 suppressed B cell proliferation and differentiation into plasma cells in response to CpG-induced activation of TLR9, a receptor that requires MyD88 for intracellular signaling. Our results indicate that ST2825 blocks IL-1R/TLR signaling by interfering with MyD88 homodimerization and suggest that it may have therapeutic potential in treatment of chronic inflammatory diseases.

Original languageEnglish
Pages (from-to)801-810
Number of pages10
JournalJournal of Leukocyte Biology
Volume82
Issue number4
DOIs
Publication statusPublished - Oct 1 2007

Fingerprint

Peptidomimetics
Dimerization
Phosphotransferases
Interleukin-1
Toll-Like Receptor 9
Protein-Serine-Threonine Kinases
Plasma Cells
Oral Administration
ST2825
Cell Differentiation
Interleukin-6
B-Lymphocytes
Chronic Disease
Cell Proliferation
Therapeutics

Keywords

  • Autoimmune diseases
  • IL-1 receptor
  • Inflammation
  • Innate immunity
  • TLR

ASJC Scopus subject areas

  • Cell Biology

Cite this

Pivotal Advance : Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. / Loiarro, Maria; Capolunghi, Federica; Fantò, Nicola; Gallo, Grazia; Campo, Silvia; Arseni, Brunilde; Carsetti, Rita; Carminati, Paolo; De Santis, Rita; Ruggiero, Vito; Sette, Claudio.

In: Journal of Leukocyte Biology, Vol. 82, No. 4, 01.10.2007, p. 801-810.

Research output: Contribution to journalArticle

Loiarro, M, Capolunghi, F, Fantò, N, Gallo, G, Campo, S, Arseni, B, Carsetti, R, Carminati, P, De Santis, R, Ruggiero, V & Sette, C 2007, 'Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound', Journal of Leukocyte Biology, vol. 82, no. 4, pp. 801-810. https://doi.org/10.1189/jlb.1206746
Loiarro, Maria ; Capolunghi, Federica ; Fantò, Nicola ; Gallo, Grazia ; Campo, Silvia ; Arseni, Brunilde ; Carsetti, Rita ; Carminati, Paolo ; De Santis, Rita ; Ruggiero, Vito ; Sette, Claudio. / Pivotal Advance : Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. In: Journal of Leukocyte Biology. 2007 ; Vol. 82, No. 4. pp. 801-810.
@article{17bac41de3594d5ba57127d436650aff,
title = "Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound",
abstract = "MyD88 is an adaptor protein, which plays an essential role in the intracellular signaling elicited by IL-1R and several TLRs. Central to its function is the ability of its Toll/IL-1R translation initiation region (TIR) domain to heterodimerize with the receptor and to homodimerize with another MyD88 molecule to favor the recruitment of downstream signaling molecules such as the serine/threonine kinases IL-1R-associated kinase 1 (IRAK1) and IRAK4. Herein, we have synthesized and tested the activity of a synthetic peptido-mimetic compound (ST2825) modeled after the structure of a heptapeptide in the BB-loop of the MyD88-TIR domain, which interferes with MyD88 signaling. ST2825 inhibited MyD88 dimerization in coimmunoprecipitation experiments. This effect was specific for homodimerization of the TIR domains and did not affect homodimerization of the death domains. Moreover, ST2825 interfered with recruitment of IRAK1 and IRAK4 by MyD88, causing inhibition of IL-1β-mediated activation of NF-κB transcriptional activity. After oral administration, ST2825 dose-dependently inhibited IL-1β-induced production of IL-6 in treated mice. Finally, we observed that ST2825 suppressed B cell proliferation and differentiation into plasma cells in response to CpG-induced activation of TLR9, a receptor that requires MyD88 for intracellular signaling. Our results indicate that ST2825 blocks IL-1R/TLR signaling by interfering with MyD88 homodimerization and suggest that it may have therapeutic potential in treatment of chronic inflammatory diseases.",
keywords = "Autoimmune diseases, IL-1 receptor, Inflammation, Innate immunity, TLR",
author = "Maria Loiarro and Federica Capolunghi and Nicola Fant{\`o} and Grazia Gallo and Silvia Campo and Brunilde Arseni and Rita Carsetti and Paolo Carminati and {De Santis}, Rita and Vito Ruggiero and Claudio Sette",
year = "2007",
month = "10",
day = "1",
doi = "10.1189/jlb.1206746",
language = "English",
volume = "82",
pages = "801--810",
journal = "Journal of Leukocyte Biology",
issn = "0741-5400",
publisher = "FASEB",
number = "4",

}

TY - JOUR

T1 - Pivotal Advance

T2 - Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound

AU - Loiarro, Maria

AU - Capolunghi, Federica

AU - Fantò, Nicola

AU - Gallo, Grazia

AU - Campo, Silvia

AU - Arseni, Brunilde

AU - Carsetti, Rita

AU - Carminati, Paolo

AU - De Santis, Rita

AU - Ruggiero, Vito

AU - Sette, Claudio

PY - 2007/10/1

Y1 - 2007/10/1

N2 - MyD88 is an adaptor protein, which plays an essential role in the intracellular signaling elicited by IL-1R and several TLRs. Central to its function is the ability of its Toll/IL-1R translation initiation region (TIR) domain to heterodimerize with the receptor and to homodimerize with another MyD88 molecule to favor the recruitment of downstream signaling molecules such as the serine/threonine kinases IL-1R-associated kinase 1 (IRAK1) and IRAK4. Herein, we have synthesized and tested the activity of a synthetic peptido-mimetic compound (ST2825) modeled after the structure of a heptapeptide in the BB-loop of the MyD88-TIR domain, which interferes with MyD88 signaling. ST2825 inhibited MyD88 dimerization in coimmunoprecipitation experiments. This effect was specific for homodimerization of the TIR domains and did not affect homodimerization of the death domains. Moreover, ST2825 interfered with recruitment of IRAK1 and IRAK4 by MyD88, causing inhibition of IL-1β-mediated activation of NF-κB transcriptional activity. After oral administration, ST2825 dose-dependently inhibited IL-1β-induced production of IL-6 in treated mice. Finally, we observed that ST2825 suppressed B cell proliferation and differentiation into plasma cells in response to CpG-induced activation of TLR9, a receptor that requires MyD88 for intracellular signaling. Our results indicate that ST2825 blocks IL-1R/TLR signaling by interfering with MyD88 homodimerization and suggest that it may have therapeutic potential in treatment of chronic inflammatory diseases.

AB - MyD88 is an adaptor protein, which plays an essential role in the intracellular signaling elicited by IL-1R and several TLRs. Central to its function is the ability of its Toll/IL-1R translation initiation region (TIR) domain to heterodimerize with the receptor and to homodimerize with another MyD88 molecule to favor the recruitment of downstream signaling molecules such as the serine/threonine kinases IL-1R-associated kinase 1 (IRAK1) and IRAK4. Herein, we have synthesized and tested the activity of a synthetic peptido-mimetic compound (ST2825) modeled after the structure of a heptapeptide in the BB-loop of the MyD88-TIR domain, which interferes with MyD88 signaling. ST2825 inhibited MyD88 dimerization in coimmunoprecipitation experiments. This effect was specific for homodimerization of the TIR domains and did not affect homodimerization of the death domains. Moreover, ST2825 interfered with recruitment of IRAK1 and IRAK4 by MyD88, causing inhibition of IL-1β-mediated activation of NF-κB transcriptional activity. After oral administration, ST2825 dose-dependently inhibited IL-1β-induced production of IL-6 in treated mice. Finally, we observed that ST2825 suppressed B cell proliferation and differentiation into plasma cells in response to CpG-induced activation of TLR9, a receptor that requires MyD88 for intracellular signaling. Our results indicate that ST2825 blocks IL-1R/TLR signaling by interfering with MyD88 homodimerization and suggest that it may have therapeutic potential in treatment of chronic inflammatory diseases.

KW - Autoimmune diseases

KW - IL-1 receptor

KW - Inflammation

KW - Innate immunity

KW - TLR

UR - http://www.scopus.com/inward/record.url?scp=34548415806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548415806&partnerID=8YFLogxK

U2 - 10.1189/jlb.1206746

DO - 10.1189/jlb.1206746

M3 - Article

C2 - 17548806

AN - SCOPUS:34548415806

VL - 82

SP - 801

EP - 810

JO - Journal of Leukocyte Biology

JF - Journal of Leukocyte Biology

SN - 0741-5400

IS - 4

ER -